Recent IPO activity in October 2026, including scheduled listings for Iambic Therapeutics and City Therapeutics, reflects a selectively open window supported by Nasdaq Composite gains of 35% year-to-date and over $120 billion in traditional IPO proceeds through September. Biotech and growth-oriented issuers have driven much of the volume, while larger candidates face scrutiny over valuations amid 19-year highs in Treasury yields and questions around AI monetization. Anthropic’s confidential filing and targeted mid-November roadshow, alongside SpaceX’s advanced positioning, anchor near-term expectations, though OpenAI’s shift to private raises at $1.4 trillion valuations highlights execution risks. Trader sentiment incorporates these catalysts against historical precedent from the 2021 cycle, with resolution hinging on filings, roadshow timing, and any last-minute macroeconomic shifts before year-end.